Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Wang, Yongjun ^a   Parker, Claire E ^b   Feagan, Brian G ^b,c   Macdonald, John K ^b,c  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BALSALAZIDE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; AMINOSALICYLIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANOREXIA; BLOATING; DENTAL CARIES; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOSCOPY; FLATULENCE; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HUMAN; LOSS OF APPETITE; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; NAUSEA; PRIORITY JOURNAL; RASH; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; COLITIS, ULCERATIVE; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; MAINTENANCE CHEMOTHERAPY; MEDICATION ADHERENCE; MESALAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; SULFASALAZINE;

EID: 84965103816     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000544.pub4     Document Type: Review

References (160)

1. Andreoli A, Cosintino R, Trotti R, Berri F, Prantera C. 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission [abstract]. Clinical Controversies in Inflammatory Bowel Disease 1987:170.
2. Ardizzone S, Petrillo M, Molteni P, Desideri S, Bianchi Porro G. Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. Journal of Clinical Gastroenterology 1995;21:287-9.
3. Bianchi Porro GB, Ardizzone S, Fasoli R, Petrillo M, Desideri S. Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative collitis [abstract]. Gut 1989;30:A1467.
4. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis?. Alimentary Pharmacology and Therapeutics 1999;13:373-9.
5. Courtney MG, Nunes DP, Bergin CF. Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis. Gastroenterology 1990;98(5 PART 2):A165.
6. Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PWN, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81.
7. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. American Journal of Gastroenterology 2012;107(7):1064-77.
8. Deventer SJH, Hommes DW, Roskam-Mul MDM, Dekker W, Gasthuis K, Wetzels A, et al. Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission. Gastroenterology 2001;120(5 Suppl 1):A454.
9. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. British Medical Journal 1983;287:23-4.
10. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses. Gut 1983;24(Suppl 10):A983.
11. Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. Journal of Crohn's and Colitis 2012;6(4):476-82.
12. Dignass A, Bokemeyer B, Mross M, Oudkerk Pool M. Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial. Journal of Crohn's and Colitis 2013;7:S153-4.
13. Dignass A, Bokemeyer B, Stijnen T, Klugmann T, Oudkerk M, Veerman H. Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Canadian Journal of Gastroenterology 2009;23.
14. Dignass A, Bokemeyer B, Stijnen T, Tan T, Borner N, Oudkerk Pool M, et al. Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis. Canadian Journal of Gastroenterology 2009;23.
15. Dignass A, Stijnen T, Mross MR, Vermeire S, Veerman H, Bhatt A. Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial. Gastroenterology 2007;132(4 Suppl 1):A502-3.
16. Dignass A, Vermeire S, Adamek H, Befrits R, Bokemeyer B, Börner N, et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. UEGW - Abstract Database 2007.
17. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology 2009;7(7):762-9.
18. Dignass AU, Bokemeyer B, Adamek HE, Mross MR, Vinter-Jensen L, Boerner N, et al. Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology 2008;134(4 Suppl 1):A494.
19. Dignass AU, Bokemeyer B, Adamek HE, Mross MR, Vinter-Jensen L, Boerner N, et al. Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis. Gastroenterology 2008;134(4 Suppl 1):A495-6.
20. Dignass AU, Bokemeyer B, Stijnen T, Veerman H. Impact of once - daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial. Gastroenterology 2009;136(5 Suppl 1):A685.
21. Dignass AU, Muls V, Silvennoinen J, Pool MO, Befrits R, Broberg P, et al. The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing. Gastroenterology 2010;1:S520.
22. Vermeire S, Befrits R, Bokemeyer B, Gill I, Hommes DW, Broberg P, et al. Efficacy of once-daily versus twice-daily mesalazine (Pentasa): Sub-analysis of the left-sided colitis population in the randomised PODIUM trial. Gastroenterology 2010;1:S522.
23. Fockens P, Mulder CJ, Tytgat GN, Blok P, Ferwerda J, Meuwissen SG, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European Journal of Gastroenterology and Hepatology 1995;7(11):1025-30.
24. Fockens P, Mulder CJJ, Ferwada J, Tytgat GNJ, and the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa) [abstract]. Gastroenterology 1993;104:A701.
25. Giaffer MH, Holdsworth CD, Lennard-Jones JE, Rodrigues CA, McIntyre PB, Manjunatha S, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Alimentary Pharmacology and Therapeutics 1992;6:479-85.
26. Green JRB, Swan CHJ, Rowlinson A, Gibson JA, Brown P, Kerr GD, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Alimentary Pharmacology and Therapeutics 1992;6:647-52.
27. Green JRB, Swan CHJ, Rowlinson AE, Gibson JA, Brown P, Kerr GD, et al. A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide. Gastroenterology 1992;102(4 PART 2):A631.
28. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months. Alimentary Pharmacology and Therapeutics 1998;12:1207-16.
29. Hanauer S, Powers B, Robinson M, Mayle J, Elson C. Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo [abstract]. Gastroenterology 1994;106:A696.
30. Hanauer SB, Sninsky CA, Robinson M, Powers BJ, McHattie JD, Mayle JE, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Annals of Internal Medicine 1996;124:204-11.
31. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, and the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997;112:718-24.
32. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial. Gut 2011;60:A37-8.
33. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): A one-year single-blind randomised trial. Gastroenterology 2011;140(5 Suppl 1):S65.
34. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflammatory Bowel Disease 2012;18(10):1885-93.
35. Ireland A, Jewell DP. Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC) [abstract]. Gastroenterology 1987;92:A1447.
36. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988;29:835-7.
37. Jewell DP, Ireland A. Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Scandinavian Journal of Gastroenterology. Supplement 1988;148:45-7.
38. Ito H, Iida M, Matsumoto T, Suzuki Y, Aida Y, Yoshida T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases 2010;16(9):1575-82.
39. Kamm MA, Colombel J, Kornbluth A, Diebold R, Barrett K, Karlstadt RG, et al. A randomized comparison of once- versus twice-Daily MMX® mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Gastroenterology 2007;132(4 Suppl 1):A510.
40. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57(7):893-902.
41. Kamm MA, Schreiber S, Butler T, Barrett K, Stephenson D, Joseph RE. Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis. UEGW Abstract Database 2006.
42. Rubin D, Dubinsky M, Panaccione R, Siegel C, Binion D, Kane S, et al. Ulcerative colitis: patients and CloseCurlyQuote; perceptions compared with other chronic diseases. Inflammatory Bowel Diseases 2008;14(S1):S22.
43. Sandborn W, Kamm M, Lichtenstein G, Barrett K, Joseph R. MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel DIseases 2008;14(S1):S24.
44. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clinical Gastroenterology and Hepatology 2003;1(3):170-3.
45. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Preference and Adherence 2008;2(2):253-8.
46. Kiilerich S, Ladefoged K, Rannem T, Ranlov P. Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis. Gastroenterology 1991;100(5 PART 2):A220.
47. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ. Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group. Gut 1992;33:252-5.
48. Kruis W, Judmaier G, Kayasseh L, Stole M, Theuer D, Scheurlen C, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. European Journal of Gastroenterology and Hepatology 1995;7:391-6.
49. Kruis W, Judmaier G, Kayasseh L, Stolte M, Scheurlen C, Hentschel E, et al. Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis [abstract]. Gastroenterology 1992;102:A649.
50. Kruis W, Stolte M. A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis. Gastroenterology 1991;100(5 PART 2):A222.
51. Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49(6):783-9.
52. Kruis W, Greinwald R, Mueller R. Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2013;144(5 Suppl 1):S768.
53. Kruis W, Jonaitis L, Pokrotnieks J, Acute G, Mikhailova TL, Horynski M, et al. Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2008;134(4 Suppl 1):A489.
54. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2011;33(3):313-22.
55. Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Alimentary Pharmacology and Therapeutics 2010;32(8):990-9.
56. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 2002;16(2):207-15.
57. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH. Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]. Gut 1986;27:A1271.
58. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baton JH, et al. Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Alimentary Pharmacology and Therapeutics 1988;2:237-43.
59. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S, and Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Digestive Diseases and Sciences 1995;40:296-304.
60. Miner P, Schwartz J, Aora S, Robinson M, Hanauer S, and the Pentasa Study Group. Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa) [abstract]. Gastroenterology 1992;102:A666.
61. Mulder CJ, Tytgat GN, Weterman IT, Dekker W, Blok P, Schrijver M, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988;95:1449-53.
62. Mulder CJJ, Tytgat GNJ, Weterman IT. Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis. Gastroenterology 1988;94(5 PART 2):A313.
63. Nilsson A, Danielsson A, Lofberg R, Benno P, Bergman L, Fausa O, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. American Journal of Gastroenterology 1995;90:381-7.
64. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary Pharmacology and Therapeutics 2005;21(9):1111-9.
65. Paoluzi OA, Pica R, Crispino P, Iacopini F, Consolazio A, Rivera M, et al. Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study. Gastroenterology 2005;128(4 Suppl 2):A585.
66. Pica R, Cassieri C, Cocco A, Marcheggiano A, Occhigrossi G, Zippi M, et al. Randomised open label trial comparing two different dosages of oral mesalazine in the maintainence treatment of ulcerative colitis. Italian Journal of Medicine 2012;1:108.
67. Kohn A, Prantera C, Caprilli R, Campieri M, Cottone M, Pallone F, et al. Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx® with Asacol®. Gastroenterology 2009;136(5 Suppl 1):390.
68. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary Pharmacology and Therapeutics 2009;30(9):908-18.
69. Rijk MCM, Lier HJJ, Tongerson JHM. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study. American Journal of Gastroenterology 1992;87:438-42.
70. Rijk MCM, van Tongersen JHM. The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission. Gastroenterology 1991;100(5 PART 2):A243.
71. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94:1383-9.
72. Riley SA, Mani V, Goodman MJ, Turnberg LA. A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis [abstract]. Gastroenterology 1987;92:A1596.
73. Riley SA, Mani V, Goodman MJ, Turnberg LA. A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC) [abstract]. Gut 1987;28:1390.
74. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1989;3:183-91.
75. Jarnerot G, Sandberg-Gertzen H. Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). a double-blind placebo controlled study. Gastroenterology 1985;88(5 PART 2):A1432.
76. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties. Gastroenterology 1986;90:1024-30.
77. Sandborn W, Kane S, Korzenik J, Lashner B, Leighton J, Mahadevan U, et al. Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results. Inflammatory Bowel Diseases 2009;15:S15.
78. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010;138(4):1286-96.
79. Travis SPL, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-6.
80. Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflammatory Bowel Diseases 2013;19(8):1681-90.
81. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Digestive Diseases and Sciences 1993;38:1837-42.
82. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in the maintenance of remission in patients with ulcerative colitis [abstract]. Gastroenterology 1992;102:A714.
83. Bardazzi G, d'Albasio G, Bonanomi AG, Trallori G, Messori A, Amorosi A, et al. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. Italian Journal of Gastroenterology 1994;26(7):334-7.
84. d'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. American Journal of Gastroenterology 1997;92(7):1143-7.
85. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remissions in ulcerative colitis with oral preparation of 5-aminosalicylic acid. British Medical Journal 1982;285:1012.
86. Eliakim R, Wengrower D, Ligumsky M, Rachmilewitz D. Comparable efficacy of oral 5-ASA (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission. Israel Journal of Medical Sciences 1990;26(1):47-9.
87. Ewe K, Becker K, Ueberschaer B. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Zeitschrift fur Gastroenterologie 1996;34(4):225-9.
88. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). American Journal of Gastroenterology 1999;94(2):427-33.
89. Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Digestive and Liver Disease 2005;37(2):92-6.
90. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Alimentary Pharmacology and Therapeutics 1992;6(1):51-9.
91. Gionchetti P, Campieri M, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al. Pentasa in maintenance treatment of ulcerative colitis [letter, comment]. Gastroenterology 1990;98:251.
92. Gionchetti P, Campieri M, Venturi A, Rizzello F, Ferretti M, Brignola C, et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Alimentary Pharmacology and Therapeutics 1996;10(4):601-5.
93. Green JR, Swan CH, Gibson JA, Kerr GD, Swarbrick ET, Thornton PC. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Alimentary Pharmacology and Therapeutics 2004;19(4):435-42.
94. Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, et al. MMX mesalamine for induction and maintenance therapy in mild-to-moderate ulcerative colitis. Gastroenterology and Hepatology 2009;5(7):494-500.
95. Karamanolis DG, Papatheodoridis GV, Xourgias V. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. European Journal of Gastroenterology and Hepatology 1996;8(11):1083-8.
96. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1997;11(5):853-8.
97. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Esherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23.
98. Mani V, Gotch P. Comparison of pharmacokinetics and colonic transit time in quiescent ulcerative colitis on mesalazine and olsalazine - A cross over study [abstract]. Gut 1994;35(Suppl 4):A124.
99. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. American Journal of Gastroenterology 2004;99(6):1122-8.
100. Odes HS. 5-Aminosalicylic acid, 1, 000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. Journal of Clinical Gastroenterology 1997;24(4):287-8.
101. Osterman MT, Aberra F, Cross R, Liakos S, McCabe RP, Shafran I, et al. A randomized controlled trial of mesalamine dose escalation for ulcerative colitis in remission. Gastroenterology 2014;146(5 Suppl 1):S149.
102. Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Digestive and Liver Disease 2002;34(11):787-93.
103. Papatheodoridis GV, Xourgias V, Sdonas T, Triantoafyllou M, Tzouvaia M, Karamanolis DG. Systematic load of 5-ASA in patients with inactive ulcerative colitis treated with olsalazine and mesalazine [abstract]. Gut 1995;37(Suppl 2 Pt 2):A54.
104. Pelech T, Fric P, Fixa B, Komarkova O. Comparison of Mutaflor and mesalazine in the maintenance treatment of inactive ulcerative colitis. Prakticky Lekar 1998;78(10):556-8.
105. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6.
106. Florholmen J. The systemic load and efficient delivery of active 5-ASA in patients with ulcerative colitis on treatment with Dipentum (Olsalazine) and Mesasael (Mesalazine) [abstract]. Gut 1994;35(Suppl 4):A121.
107. Stoa-Birketvedt G, Florholmen J. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. Alimentary Pharmacology and Therapeutics 1999;13:357-61.
108. Tragnone A, Elmi G, Tagliente C, Bazzocchi G, Dina R, Euseb V, et al. Oral 5-aminosalicylic acid therapy for the prevention of relapse in patients with ulcerative colitis (UC) during remission: a new therapeutical approach by using 5-ASA tablets 800 mg. A multicenter controlled randomized trial [abstract]. Gastroenterology 1996;110:A1030.
109. Archimandritis A, Hatzis G, Konstandinidis A, Paraskeva K, Tjivras M, Skandalis N. Disposition of 5-ASA by olsalazine (Dipentum) and mesalazine (Asacol) in patients with ulcerative colitis in remission [abstract]. Gut 1996;39(Suppl 3):A75.
110. Tzivras M, Konstandinidis A, Hatzis G, Paraskeva K, Skandalis N, Archimandritis A. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. European Journal of Gastroenterology and Hepatology 1997;9(7):729-30.
111. Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflammatory Bowel Diseases 2007;13(9):1115-20.
112. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23:1567-74.
113. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings?. New England Journal of Medicine 1995;332(17):1125-31.
114. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;2(8044):892-5.
115. Beaulieu DB Schwartz DA. Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME. MedScape CME Gastroenterology Posted 12/22/2009.
116. Brixner D, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy Annual Meeting. San Diego, CA, 2007.
117. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences 1983;28:609-15.
118. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. New England Journal of Medicine 1973;289:491-5.
119. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. British Journal of Clinical Pharmacology 1982;14:405-8.
120. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. American Journal of Gastroenterology 2007;102(7):1417-26.
121. Fleig WE, Laudage G, Sommer H, Wellmann W, Stange EF, Riemann J. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion 1988;40(3):173-80.
122. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 1993;7:369-83.
123. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
124. Hardy JG, Healey JNC, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 1987;1:273-80.
125. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
126. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
127. Ireland A, Jewell DP. Olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology 1988;23(suppl 148):101-3.
128. Jarnerot G. Withdrawal rates because of diarrhoea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose titrated [abstract]. Gastroenterology 1996;110:A932.
129. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology 2001;96(10):2929-33.
130. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine 2003;114(1):39-43.
131. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23(5):577-85.
132. Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. Journal of Managed Care Pharmacy 2008;14(1 Suppl A):s2-12.
133. Kjaergaard N, Ambrosius Christensen L, Lauritsen JG, Rasmussen N, Honore Hansen S. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scandinavian Journal of Gastroenterology 1989;24:891-6.
134. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine 1980;303:1499-502.
135. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology 1999;94(7):1733-42.
136. Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. American Journal of Gastroenterology 2006;101:S447.
137. Misiewitz JJ, Lennard-Jones JE, Connell AM, Baron JH, Jones FA. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.
138. Myers B, Evans DNW, Rhodes J, Evans BK, Hughes BR, Lee MG, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987;28:196-200.
139. Nielsen OH. Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1982;17:389-93.
140. Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. British Journal of Clinical Pharmacology 1983;16:738-40.
141. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics 1972;181:555-62.
142. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulfasalazine. Scandinavian Journal of Gastroenterology 1987;22:332-6.
143. Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskou S, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982;83:1062-70.
144. Riley SA, Lecarpentier J, Mini V, Goodman JJ, Mandal BK, Turnberg LA. Sulfasalazine induced seminal abnormalities in ulcerative colitis: result of mesalazine substitution. Gut 1987;28:1008-12.
145. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology 2002;97(12):2939-41.
146. Sandborn WJ, Hanauer SB, Buch A. Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal. American Journal of Gastroenterology 2002;97:S263.
147. Sandborn WJ, Hanauer SB. The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: A systematic review. American Journal of Gastroenterology 2002;97:S269.
148. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2003;17(1):29-42.
149. Schroeder H, Campbell DES. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics 1972;13:539-51.
150. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
151. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2003;18(2):191-8.
152. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic reults in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavica 1942;110:557-90.
153. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: Final report on a therapeutic trial. British Medical Journal 1955;4947:1041-8.
154. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. British Medical Journal 1959;i:387-94.
155. Van Hees PAM, Bakker JH, Tongeren JHM. Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut 1980;21:632-5.
156. Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 1982;23:1081-7.
157. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD000544.pub3]
158. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine 1993;118:540-9.
159. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflammatory Bowel Diseases 1997;3:65-78.
160. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD000544.pub2]